Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Management of vaccine safety in Korea.

Choe YJ, Bae GR.

Clin Exp Vaccine Res. 2013 Jan;2(1):40-5. doi: 10.7774/cevr.2013.2.1.40. Epub 2013 Jan 15.

2.

Successful introduction of an underutilized elderly pneumococcal vaccine in a national immunization program by integrating the pre-existing public health infrastructure.

Yang TU, Kim E, Park YJ, Kim D, Kwon YH, Shin JK, Park O.

Vaccine. 2016 Mar 18;34(13):1623-9. doi: 10.1016/j.vaccine.2016.01.043. Epub 2016 Feb 3.

PMID:
26850759
3.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

4.

Allergic reactions to Japanese encephalitis vaccine.

Plesner AM.

Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. Review. Erratum in: Immunol Allergy Clin North Am. 2004 May;24(2):335.

PMID:
14753386
5.

Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.

Sohn HS, Suh DC, Jang E, Kwon JW.

J Manag Care Pharm. 2010 Jan-Feb;16(1):32-45.

6.

Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).

Wharton M, Strikas RA, Harpaz R, Rotz LD, Schwartz B, Casey CG, Pearson ML, Anderson LJ; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee.

MMWR Recomm Rep. 2003 Apr 4;52(RR-7):1-16.

7.

Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010.

Choe YJ, Cho H, Kim SN, Bae GR, Lee JK.

Vaccine. 2011 Oct 13;29(44):7727-32. doi: 10.1016/j.vaccine.2011.07.129. Epub 2011 Aug 7.

PMID:
21827815
8.

Immunization: a key to primary health care.

Program for Appropriate Technology in Health PATH.

Health Technol Dir. 1983 Jan;3(1):1-6.

PMID:
12268557
9.
10.

[Vaccine safety].

Weisser K, Barth I, Keller-Stanislawski B.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009 Nov;52(11):1053-64. doi: 10.1007/s00103-009-0961-y. Review. German.

PMID:
19771402
11.

Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.

Baker MA, Nguyen M, Cole DV, Lee GM, Lieu TA.

Vaccine. 2013 Dec 30;31 Suppl 10:K98-112. doi: 10.1016/j.vaccine.2013.04.088.

PMID:
24331080
12.

Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism.

Institute of Medicine (US) Immunization Safety Review Committee; Stratton K, Gable A, Shetty P, McCormick M, editors.

Washington (DC): National Academies Press (US); 2001.

13.

Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.

LaRussa PS, Edwards KM, Dekker CL, Klein NP, Halsey NA, Marchant C, Baxter R, Engler RJ, Kissner J, Slade BA.

Pediatrics. 2011 May;127 Suppl 1:S65-73. doi: 10.1542/peds.2010-1722J. Epub 2011 Apr 18.

PMID:
21502239
15.

Role of pharmacovigilance on vaccines control*.

Kuçuku M.

J Rural Med. 2012;7(1):42-5. doi: 10.2185/jrm.7.42. Epub 2012 Jul 7.

16.

Enhancing public confidence in vaccines through independent oversight of postlicensure vaccine safety.

Salmon DA, Moulton LH, Halsey NA.

Am J Public Health. 2004 Jun;94(6):947-50.

17.

Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization.

Amarasinghe A, Black S, Bonhoeffer J, Carvalho SM, Dodoo A, Eskola J, Larson H, Shin S, Olsson S, Balakrishnan MR, Bellah A, Lambach P, Maure C, Wood D, Zuber P, Akanmori B, Bravo P, Pombo M, Langar H, Pfeifer D, Guichard S, Diorditsa S, Hossain MS, Sato Y.

Vaccine. 2013 Apr 18;31 Suppl 2:B108-14. doi: 10.1016/j.vaccine.2012.10.119. Review.

PMID:
23598471
18.

Communicating vaccine safety in the context of immunization programs in low resource settings.

Arwanire EM, Mbabazi W, Mugyenyi P.

Curr Drug Saf. 2015;10(1):68-75.

PMID:
25859678
19.

Priorities for the National Vaccine Plan.

Institute of Medicine (US) Committee on Review of Priorities in the National Vaccine Plan.

Washington (DC): National Academies Press (US); 2010.

20.

Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.

Izurieta P, Kim WJ, Wie SH, Lee J, Lee JS, Dramé M, Vaughn DW, Schuind A.

Vaccine. 2015 Jun 4;33(24):2800-7. doi: 10.1016/j.vaccine.2015.04.027. Epub 2015 Apr 21.

Supplemental Content

Support Center